ReviewCancer management and research2014
Treating advanced melanoma: current insights and opportunities.
Review in Cancer management and research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta-analysis and systematic review.Cancer medicine · 2019Pooled it
- Ultrasound-guided intra-tumoral administration of directly-injected therapies: a review of the technical and logistical considerations.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Review
- Impact of [Diagnostics (Basel, Switzerland) · 2023Article
- Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma.Human vaccines & immunotherapeutics · 2022Review
- Protein Expression in Metastatic Melanoma and the Link to Disease Presentation in a Range of Tumor Phenotypes.Cancers · 2020Article
- Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.Neoplasia (New York, N.Y.) · 2018Article
- A practical guide to the handling and administration of talimogene laherparepvec in Europe.OncoTargets and therapy · 2017Review
- Article
- Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future.Current treatment options in oncology · 2016Review
- Essential role for acid sphingomyelinase-inhibited autophagy in melanoma response to cisplatin.Oncotarget · 2016Article
- Pharmacological targeting of guanosine monophosphate synthase suppresses melanoma cell invasion and tumorigenicity.Cell death and differentiation · 2015Article
- Glucose transporter isoform 1 expression enhances metastasis of malignant melanoma cells.Oncotarget · 2015Article
- A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.Cancer gene therapy · 2015Review
- Alternative Treatments For Melanoma: Targeting BCL-2 Family Members to De-Bulk and Kill Cancer Stem Cells.The Journal of investigative dermatology · 2015Review
- Improving Melanoma Path Reports: the Importance of Histopathological Parameters in Diagnosis of Cutaneous Melanoma.Maedica · 2015Article
- Somatic DNA mutation analysis in targeted therapy of solid tumours.Translational pediatrics · 2015Review
- Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.American journal of cancer research · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whereas thin melanomas have an excellent prognosis after sufficient surgical treatment, melanoma disease in advanced stages is still a therapeutic challenge. After decades of frustrating studies, new therapeutic strategies have come up in the past few years. On the one hand, increasing insights into the molecular aberrations in melanoma have led to specific "targeted" therapies to affect only the mutated tumor cells, as in many other types of cancers. Today there are few "targeted" substances which are already approved and successfully used for single or combination therapy, but many others are under development. While on the other hand, nonpersonalized strategy substances have been developed successfully inducing an immunologic tumor response. Both kinds of therapy have been found to result in an improvement not only of the response rate, but also of the overall survival in metastatic disease, which represents a milestone in melanoma therapy. However, using these therapies there is still much to learn regarding the effects, the side effects, and the limitations of these promising substances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.